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ABSTRACT 
To determine serum thyroxine-binding globulin 
(TBG) levels, we used radioimmunoassay, and com- 
pared the results obtained with other tests in 231 
patients with chronic hepatitis B virus infection to 
evaluate its clinical implications. All of these patients 
were hepatitis B surface antigen (HBsAg)-positive. 
Among them, 38 patients had hepatocellular car- 
cinoma (HCC), 18 had chronic persistent hepatitis, 70 
had chronic lobular or active hepatitis (grouped as 
CAH), 31 had active cirrhosis (AC), 25 had inactive 
cirrhosis, 20 had decompensated cirrhosis, and 29 were 
“healthy” HBsAg carriers. Twenty-seven patients with 
acute hepatitis, 12 with cancer metastasis to the liver, 
and 81 normal adults served as disease or normal 
controls. The results showed that serum TBG level 
increased significantly in patients with CAH, AC, or 
HCC. Serum TBG did not correlate with albumin or 
bilirubin level, but correlated with alanine ami- 
notransferase (ALT) positively in patients with CAH 
( p  < 0.001) and negatively in patients with HCC 
( p  < 0.01) (slope difference p < 0.05). Serial determi- 
nation of serum TBG and ALT also showed parallel 
changes in 15 patients with CAH, but not in nine 
patients with HCC. In contrast, the fall and rise of 
serum TBG levels in patients with HCC coincided with 
tumor resection and recurrence. The data suggest that 
serum TBG elevation in patients with hepatitis activity 
is the result of hepatocellular damage, whereas that in 
patients with HCC is due to increased synthesis. 
Whether serum TBG elevation without concomitant 
rise of ALT could be used as a marker of HCC awaits 
further study. 
COMMENTS 
The article under comment focuses attention on the 
relevance in HCC of thyroxine-binding globulin (TBG), 
the major transport protein of thyroxine (T,) in human 
plasma. In addition, a recent case report describes a 
patient with HCC in whom greatly raised serum T4 
levels were responsible for weight loss and weakness 
that had been attributed initially to hyperthyroidism (1). 
The patient was, however, euthyroid clinically, and 
hyperthyroidism was excluded by the finding of a 
normal-free T4 index and a low triiodothyronine (T,) 
resin uptake and 24-hr 1311 uptake by the thyroid gland. 
The serum level of thyroid-stimulating hormone (TSH) 
was normal. A high concentration of TBG was measured 
in the patient’s serum, and the euthyroid hyperthyrox- 
inemia was ascribed to increased binding of T, to this 
protein. 
When larger numbers of patients with HCC are 
studied, it becomes evident that raised serum T, 
concentrations are not uncommon. Seven of 39 of our 
patients (18%) (2) had a raised level, as did 22% (12 of 59) 
of those of Alexopoulos et al. (3). These patients, too, 
were euthyroid clinically and had normal-free T, indices, 
low T, resin uptakes, normal serum TSH concentrations 
and raised serum TBG levels. Although the cause of the 
high serum concentration of TBG in patients with HCC 
has not been established with certainty, the protein is 
almost certainly synthesized and secreted by the ma- 
lignant hepatocytes (2). TBG is normally derived from 
hepatocytes (4), and HCC cells growing in tissue culture 
have been shown to produce the globulin (5 ) .  Apart from 
HCC, other causes of increased hepatic secretion of TBG 
are congenital, increased serum estrogen levels and 
various forms of benign hepatic disease (6).  A high 
circulating level of the binding protein is the most 
common explanation for euthyroid hyperthyroxinemia. 
The number of patients with increased TBG values in 
our series (2) and that of Alexopoulos et al. (3) was 17 
(44%) and 15 (25%), respectively. Thus T, levels are less 
often raised in patients with HCC and elevated serum 
TBG levels than would be expected. A probable expla- 
nation for this phenomenon is suggested by the finding 
of a reduced mean T, TBG ratio in such patients (21, 
indicating a lesser affinity of binding of T, to the TBG 
produced by malignant hepatocytes. 
Ironically, in the only reported situation of a patient 
with both HCC and hyperthyroidism, although the 
serum TBG concentration was elevated, free T, and T, 
levels were increased, and circulating levels of TSH were 
inappropriately raised (7). The hyperthyroidism was 
attributed to ectopic synthesis by the tumor of a 
substance that stimulated the release of TSH from the 
pituitary gland. 
Huang and Liaw found that 71% of 38 patients with 
HCC had raised serum TBG levels. With this preva- 
lence, and the 69% reported by Terui et al. (8), it has, 
not surprisingly, been suggested that TBG be used as 
a serum marker for this tumor. In other published 
series, however, lower prevalences-25% (3), 32% (9) 
and 44% (2)-were recorded. Thus the sensitivity of 
TBG as a marker for HCC falls far short of that of 
a-fetoprotein and of other tumor markers such as 
des-y-carbow prothrombin and tumor-specific isoen- 
zymes of y-glutamyltransferase. Moreover, increased 
serum concentrations of TBG often occur in a variety 
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of benign hepatic diseases characterized by paren- 
chymal inflammation, including acute hepatitis, CAH, 
cirrhosis and PBC. For example, Huang and Liaw 
found raised TBG levels in 80% of patients with CAH 
and 71% of those with posthepatitic cirrhosis. The high 
serum levels of the binding protein in these conditions 
parallel those of the aminotransferases, implying that 
TBG leaks into the circulation from damaged hepa- 
tocytes. Because cirrhosis is one of the more important 
disorders to be differentiated from HCC, the specificity 
of TBG as a marker of this tumor might also be 
questioned. As reported by Huang and Liaw and our- 
selves (a), cirrhotic patients with inactive cirrhosis (i.e., 
with normal serum aminotransferase levels) are known 
to have normal serum TBG levels. Because HCC 
usually coexists with inactive rather than active cir- 
rhosis, Huang and Liaw propose that a raised serum 
TBG value in a patient with a normal ALT level may 
be a useful marker of HCC. 
Another possible role for TBG in the diagnosis of HCC 
arises from the observations of Alexopoulos et al. (3). In 
long-term monitoring of cirrhotic patients they observed 
that for those patients in whom HCC developed, the 
serum TBG concentration rose, whereas for those 
patients in whom HCC did not develop, the level 
remained the same or even decreased. The raised TBG 
values preceded the clinical recognition of the tumor and 
in some cases even an increase in the serum 
a-fetoprotein level. They have therefore suggested that 
serum TBG may be of value in the early recognition of 
HCC arising in a cirrhotic liver. 
MICHAEL C. KEw, M.D. 
Witwatersrand University Medical School 
Johannesburg, 21 93 South Africa 
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